Clinical trial NCT04296253: Biomarkers and SNP-polymorphisms in Post-infarction Cardiac Remodeling
Official title: Angiogenic Growth Factors, Pro- and Anti-inflammatory Biomarkers, and Genetic Polymorphisms of Their Promoter Regions in Patients With Post-infarction Cardiac Remodeling
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Myocardial Infarction
Keywords: remodeling
inflammation
polymorphism
endotoxin
heart failure
Lead sponsor: Tomsk National Research Medical Center of the Russian Academy of Sciences
Sponsor class: OTHER
First posted: 2020-03-05
Enrollment: 200
Sex: ALL
Minimum age (years): 30
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with acute myocardial infarction with ST segment elevation, who underwent coronary angiography within 24 hours of the onset of the disease.

Brief summary: The purpose of this study is to explore the serum levels of pro- and anti-inflammatory biomarkers and angiogenic growth factors and SNP polymorphisms of the promoter regions of their genes as well as to determine their role in the development of adverse cardiac remodeling in patients with acute ST-segment elevation myocardial infarction.

Detailed description: The widespread introduction of modern methods of treatments of myocardial infarction in routine clinical practice has lead not only to a decrease in mortality, but also to an increase in the number of patients with chronic heart failure. It is known that inflammation develops in myocardial infarction in response to cell damage, which is accompanied by activation of the cells of the immune system and eventually with scarring. Chronic aseptic inflammation is not only a universal biological reaction in response to necrosis of cardiomyocytes, but the cellular molecular basis of post-infarction cardiac remodeling. At the same time, the imbalance of pro- and anti-inflammatory mediators can have some negative effects on the healing processes of the damaged myocardium and subsequent remodeling of the heart. In adverse heart remodeling, elevated levels of proinflammatory cytokines (IL-1β, IL-6, TNF-α, etc.) and reduced secretion of anti-inflammatory cytokines (IL-4, IL-10, etc.) persist for a long time.

Recently, the endotoxin hypothesis of cytokine production has been of great interest among scientists. Endotoxin is a molecule of the lipopolysaccharide (LPS) of the outer cell wall of gram-negative bacteria. LPS is a powerful inducer of cytokine release, and chronic endotoxin load is at least one of the reasons for the activation of the innate immune system. One of the most important and unresolved problems in pathophysiology is the study of the nature of the inflammatory response, or rather the cytokine response cascade, reparation and neoangiogenesis developing in the myocardium in response to ischemic damage, as well as genetically determined regulation of these processes. Factors determining the dual role of cytokines in the development of adverse cardiac remodeling can be polymorphisms of their genes, in particular, single nucleotide polymorphism of genes - SNP (single nucleotide polymorphism) with replacement of one nucleotide by another. SNP in promoter regions regulate the intensity of gene expression, different levels of secretion and function of interleukins, growth factors, and, accordingly, their biological effects. Uncovering the mechanisms that regulate the secretion of angiogenic growths factors, pro- and anti-inflammatory cytokines in patients with AMI could potentially become the basis for developing new treatment tactics based on modulating the immune response and neoangiogenesis in AMI by introducing into ischemic tissues of cytokines or angiogenic growth factors in the form recombinant proteins or as a part of genetic constructs to stimulate regeneration.

A total of 200 patients with acute primary myocardial infarction with ST segment elevation will be recruited. Upon admission, all patients receive standard therapy, as recommended for the treatment of myocardial infarction. Within 24 hours of admission, coronary angiography and revascularization of the infarct-related artery are performed. On the days 1 and 7 of hospitalization and on the day of discharge, blood will be taken to determine the dynamics of serum concentrations of pro- and anti-inflammatory biomarkers, markers of myocardial necrosis; gene polymorphisms will be studied; echocardiography will be performed to assess the structural and functional characteristics of the heart after AMI. After 3 and 12 months, patients undergo studies to dynamically assess the structural and functional state of the heart.

Eligibility criteria: Inclusion Criteria:

* Age ≥ 18 years at time of randomization
* Patients with acute coronary syndrome with ST segment elevation
* Signed informed consent to participate in the study
* Admission to the intensive care unit within 24 hours from the onset of the disease
* Coronary angiography within 24 hours of the onset of the disease

Exclusion Criteria:

* Long persistent form of atrial fibrillation
* Valvular heart disease
* Shock of different genesis
* Multiple organ failure
* Chronic heart failure with a severe decrease in the left ventricular ejection fraction
* Sepsis
* Severe concomitant pathology

Primary outcomes:
measure: Change in the left ventricular end-diastolic volume index (percent)
timeFrame: 1 year
Secondary outcomes:
measure: Incidence of mortality (percent)
timeFrame: 1 year
measure: Incidence of stroke (percent)
timeFrame: 1 year
measure: Incidence of unstable angina (percent)
timeFrame: 1 year
measure: Incidence of chronic heart failure > II NYHA (percent)
timeFrame: 1 year
measure: Incidence of recurrent myocardial infarction (percent)
timeFrame: 1 year
measure: Change in pro-inflammatory cytokine (pg/mL)
timeFrame: 1 year
measure: Change in anti-inflammatory cytokine (pg/mL)
timeFrame: 1 year
measure: Change in angiogenic growth factor (pg/mL)
timeFrame: 1 year
measure: Change in endotoxin (ng/mL)
timeFrame: 1 year
Other outcomes:
measure: CE 1: cardiovascular mortality + myocardial reinfarction + unstable angina (percent)
timeFrame: 1 year
measure: CE 2: cardiovascular mortality + myocardial reinfarction + chronic heart failure > II NYHA (percent)
timeFrame: 1 year
Locations:
city: Tomsk
country: Russian Federation
facility: Cardiology Research Institute of Tomsk National Research Medical Center of the Russian Academy of Sciences
state: Tomskii Region
Study officials:
affiliation: Cardiology Research Institute, Tomsk NRMC
name: Vyacheslav Ryabov, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: